Home/ Stocks/ TRVI

Trevi Therapeutics, Inc. Common Stock

TRVI XNAS

$14.50 +0.69 (+4.91%) ▲ 15-min delayed

Open

$14.46

High

$15.35

Low

$14.39

Volume

1.99M

Market Cap

$2.06B

About Trevi Therapeutics, Inc. Common Stock

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 34 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-13,192,000	$-0.09
Q3 2025	$0	$-11,802,000	$-0.08
Q2 2025	$0	$-12,301,000	$-0.09
Q1 2025	$0	$-10,340,000	$-0.09

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026

Calendar →

Related Market News

No specific coverage for TRVI yet. Check out our latest market news or earnings calendar.

Get TRVI Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Trevi Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.